MDxHealth has announced the discontinuation of its Resolve UTI test and associated laboratory operations due to an adverse reimbursement environment, specifically a $10.4 million recoupment demand from Novitas. This strategic pivot allows the company to concentrate resources on its core prostate cancer diagnostics, which reported an 11% increase in pro forma revenue to $23.9 million, excluding the discontinued segment. However, the company faced a widening pro forma operating loss of $7.9 million, attributed to costs associated with the ExoDx acquisition.
The decision to exit the UTI market is significant for MDxHealth as it aims to streamline operations and enhance focus on its prostate cancer portfolio, which is projected to grow by 20%-26% in 2026, with updated revenue guidance of $110 million to $115 million. The integration of AI initiatives is also expected to bolster operational efficiencies and customer engagement.
For market professionals, the key takeaway is that while MDxHealth navigates immediate financial challenges, its strategic refocus on prostate cancer diagnostics positions it for potential long-term growth in a high-demand sector.
Source: fool.com